ArticleInvestigational new drugs2017

A phase I dose-escalation study of Selumetinib in combination with Erlotinib or Temsirolimus in patients with advanced solid tumors.

Jeffrey R Infante et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.